0001181431-13-063390.txt : 20131218 0001181431-13-063390.hdr.sgml : 20131218 20131218163028 ACCESSION NUMBER: 0001181431-13-063390 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20131216 FILED AS OF DATE: 20131218 DATE AS OF CHANGE: 20131218 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALIMERA SCIENCES INC CENTRAL INDEX KEY: 0001267602 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6120 WINDWARD PARKWAY STREET 2: STE 290 CITY: ALPHARETTA STATE: GA ZIP: 30005 BUSINESS PHONE: 6789905740 MAIL ADDRESS: STREET 1: 6120 WINDWARD PARKWAY STREET 2: STE 290 CITY: ALPHARETTA STATE: GA ZIP: 30005 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Caballa Susan CENTRAL INDEX KEY: 0001489530 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34703 FILM NUMBER: 131285533 MAIL ADDRESS: STREET 1: 6120 WINDWARD PARKWAY STREET 2: SUITE 290 CITY: ALPHARETTA STATE: GA ZIP: 30005 4 1 rrd397837.xml FORM 4 X0306 4 2013-12-16 0 0001267602 ALIMERA SCIENCES INC ALIM 0001489530 Caballa Susan 6120 WINDWARD PARKWAY, SUITE 290 ALPHARETTA GA 30005 0 1 0 0 SVP,Regulatory&Medical Affairs Employee Stock Option (Right to Buy) 2.47 2013-12-16 4 A 0 90000 0 A 2023-12-15 Common Stock 90000 90000 D Employee Stock Option (Right to Buy) 2.47 2013-12-16 4 A 0 35000 0 A 2023-12-15 Common Stock 35000 35000 D This option shall vest in forty-eight equal monthly installments beginning on January 16, 2014, provided that the Reporting Person remains continuously employed by the Issuer through each vesting period. This option shall become exercisable only upon approval by the U.S. Food and Drug Administration of the Issuer's New Drug Application for ILUVIEN(R) for the treatment of diabetic macular edema, provided that such approval occurs on or before December 31, 2014, in which case this option shall vest in forty-eight equal monthly installments beginning on January 16, 2014, provided further that the Reporting Person remains continuously employed by the Issuer through each vesting period. /s/ Susan Caballa 2013-12-17